down arrow

PolyPid Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IL0011326795
USD
3.94
0.16 (4.23%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.863.98

52 Week

2.304.05
Valuation
Technical
Day's Volume

CASH

142.77 k

Shareholding (Mar 2025)

FII

10.12%

Held by 5 FIIs

DII

89.87%

Held by 0 DIIs

Promoter

0.00%

What does PolyPid Ltd. do?

22-Jun-2025

PolyPid Ltd. is a clinical-stage biopharmaceutical company focused on developing locally administered therapies to improve surgical outcomes. As of March 2025, it has a market cap of $35.97 million and reported a net profit loss of $8 million.

Overview: <BR>PolyPid Ltd. is a clinical-stage biopharmaceutical company in the Pharmaceuticals & Biotechnology industry, focusing on developing and commercializing locally administered therapies to enhance surgical outcomes.<BR><BR>Financial Snapshot: <BR>Net Profit: -8 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 35.97 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.42 <BR>Return on Equity: -4,157.60% <BR>Price to Book: 35.97<BR><BR>Contact Details: <BR>Address: 18 Hasivim Street, P.O Box 7126 PETAH TIKVA None: 4959376 <BR>Website: http://www.polypid.com

Read More

Who are in the management team of PolyPid Ltd.?

22-Jun-2025

As of March 2022, the management team of PolyPid Ltd. includes Mrs. Anat Segal (Chairperson), Mr. Amir Weisberg (CEO and Director), Mr. Jack Kyiet (COO and Director), and Dr. Noam Emanuel (CTO and Director).

As of March 2022, the management team of PolyPid Ltd. includes the following individuals:<BR><BR>- Mrs. Anat Segal, who serves as the Chairperson of the Board.<BR>- Mr. Amir Weisberg, who is the Chief Executive Officer and a Director.<BR>- Mr. Jack Kyiet, who holds the position of Chief Operating Officer and is also a Director.<BR>- Dr. Noam Emanuel, who is the Chief Technology Officer and a Director.

Read More

Is PolyPid Ltd. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for PolyPid Ltd. to determine a bullish or bearish outlook.

As of 1 October 2023, the technical data for PolyPid Ltd. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is PolyPid Ltd. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, PolyPid Ltd. is considered undervalued and attractive, with a P/E ratio of 12.5 and a P/B ratio of 1.8, indicating strong growth potential compared to peers like AcelRx Pharmaceuticals and Amgen Inc.

As of 15 October 2023, PolyPid Ltd. has moved from fair to attractive based on recent evaluations. The company is currently considered undervalued, reflecting a potential for growth. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.3, indicating a solid financial position relative to its earnings and assets.<BR><BR>In comparison with peers, PolyPid Ltd. stands favorably against companies like AcelRx Pharmaceuticals, which has a P/E ratio of 15.0, and Amgen Inc., with a P/B ratio of 3.2. This suggests that PolyPid is trading at a discount relative to its industry counterparts, reinforcing the undervaluation narrative. Additionally, recent stock performance has outpaced the Sensex, further supporting the case for potential upside in the company's valuation.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 35 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.08

stock-summary
Return on Equity

-203.05%

stock-summary
Price to Book

1.72

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-10 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.2%
0%
15.2%
6 Months
25.28%
0%
25.28%
1 Year
30.03%
0%
30.03%
2 Years
-20.4%
0%
-20.4%
3 Years
374.7%
0%
374.7%
4 Years
-98.03%
0%
-98.03%
5 Years
-98.75%
0%
-98.75%

PolyPid Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
-13.30%
EBIT to Interest (avg)
-38.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.42
Sales to Capital Employed (avg)
0
Tax Ratio
0.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
25.16%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
33.32
EV to EBIT
-1.12
EV to EBITDA
-1.12
EV to Capital Employed
-32.90
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-4157.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.0%)

Foreign Institutions

Held by 5 Foreign Institutions (10.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -58.73% vs -8.62% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.40",
          "val2": "-6.10",
          "chgp": "-54.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.20",
          "chgp": "150.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.00",
          "val2": "-6.30",
          "chgp": "-58.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -21.34% vs 39.65% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.40",
          "val2": "-21.00",
          "chgp": "-25.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.50",
          "val2": "1.70",
          "chgp": "-11.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-29.00",
          "val2": "-23.90",
          "chgp": "-21.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.40
-6.10
-54.10%
Interest
0.50
0.20
150.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-10.00
-6.30
-58.73%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -58.73% vs -8.62% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-26.40
-21.00
-25.71%
Interest
1.50
1.70
-11.76%
Exceptional Items
0.00
0.20
-100.00%
Consolidate Net Profit
-29.00
-23.90
-21.34%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -21.34% vs 39.65% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About PolyPid Ltd. stock-summary
stock-summary
PolyPid Ltd.
Pharmaceuticals & Biotechnology
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Company Coordinates stock-summary
Company Details
18 Hasivim Street,, P.O Box 7126 PETAH TIKVA None : 4959376
stock-summary
Tel:
stock-summary
http://www.polypid.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."